Graham Parry has given his Hold rating due to a combination of factors surrounding Novartis AG’s recent approval of Kisqali. The drug’s approval for use in early breast cancer with a broad label ...
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...
Some results have been hidden because they may be inaccessible to you